Registry to evaluate treatment patterns and outcomes in advanced pancreatic cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to systematically collect and analyze real-world data on treatment patterns, clinical outcomes, and toxicities among patients with advanced pancreatic ductal adenocarcinoma (PDAC) in Austria. It will involve 1000 adult patients who are receiving first-line chemotherapy for locally advanced inoperable or metastatic PDAC. The study will focus on patients undergoing palliative treatment with approved chemotherapeutic agents, including platinum-based therapies and gemcitabine. Data collected will help to understand the effectiveness and safety of current treatment approaches in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 years, female and male
* ECOG (Eastern Cooperative Oncology Group) Scale 0-2
* Diagnosis of histologically confirmed locally advanced inoperable and/or metastatic PDAC
* Patients undergoing palliative 1st line therapy with a platinum- or gemcitabine- based chemotherapy in case of previous (neo)adjuvant therapy also patients who receive nal-Irinotecan/5-FU/Leukovorin as palliative first line are eglible
* Signed informed consent for prospective patients, for retrospective cases no informed consent is required

Exclusion Criteria:

* Patients with locally advanced operable PDAC who do not receive palliative chemotherapy
* Patients with locally advanced borderline resectable PDAC who do not receive palliative chemotherapy

Where it's running

• Medical University Graz Department of Oncology
  Graz, Styria, Austria Recruiting
• Ordensklinikum Linz
  Linz, Upper Austria, Austria Recruiting
• Landesklinikum Amstetten
  Amstetten, Austria Recruiting
• Landesklinikum Feldkirch
  Feldkirch, Austria Recruiting
• Krankenhaus der Barmherzigen Brüder
  Graz, Austria Recruiting
• Universitätsklinikum Innsbruck,
  Innsbruck, Austria Recruiting

Study contacts

• Principal investigator: Jakob M Riedl, Pri. Doz. Dr. Dr. — Medical University Graz Department of Oncology
• Study coordinator: Jakob M Riedl, Priv. Doz. Dr. Dr.
• Email: j.riedl@medunigraz.at
• Phone: +43 316 385 32015

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery

  This pilot test uses contrast-enhanced ultrasound to see if it can help detect return of pancreatic cancer after surgery in patients being watched with CT scans.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07910383

• Combination of ivermectin with standard skin-protective care for daraxonrasib-related skin toxicity in pancreatic cancer

  This study tests whether adding ivermectin to standard preventive skin care helps people with pancreatic cancer who develop skin side effects from daraxonrasib.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07895498

• Becotatug Vedotin Plus Anti-PD-1 and S-1 in EGFR-Positive Advanced Pancreatic Cancer

  This study tests a three-drug regimen (becotatug vedotin, an anti-PD-1 therapy, and S-1) in adults with EGFR-positive advanced pancreatic cancer who have not responded to at least one prior therapy.

  Recruiting Ningbo Medical Center Lihuili Hospital · Ningbo, Zhejiang · NCT07892573

• Blood protein biomarkers to help diagnose pancreatic cancer in adults

  This study tests whether blood protein biomarkers can help detect pancreatic ductal adenocarcinoma and tell it apart from chronic pancreatitis and mucinous pancreatic lesions, and whether combining markers with CA 19-9 improves accuracy.

  Recruiting Grigore T. Popa University of Medicine and Pharmacy · Iași · NCT07875582

• Lm-LLO-TT and Gemcitabine in Unresectable Pancreatic Cancer (Phase 1)

  This early-stage study tests whether giving Lm-LLO-TT directly into the belly with low-dose gemcitabine is safe and tolerable for adults with previously treated, unresectable or metastatic pancreatic cancer.

  Recruiting Phase 1 Matter Bio, Inc. · The Bronx, New York · NCT07828236

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.